This webinar took place on Wednesday, June 24, 2026
The recording of this webinar is available to ISFTD Members.
Please click the button below to log in. Not a member? Join today!
Join us for our next ISFTD EMCR webinar: Drug Development & Clinical Trials for FTD! This exciting session brings together a fantastic panel of speakers from academia and industry to explore the rapidly evolving landscape of FTD therapeutics. Featuring early- and mid-career researchers and clinicians, the webinar will cover the full translational pipeline, from biological drug development, to clinical drug trials in humans, to innovative neuromodulation approaches being tested across diverse linguistic, cultural, and healthcare settings. If you are interested in how promising discoveries move from the lab bench to real-world interventions for people living with FTD, this webinar is for you.
Program
– Opening remarks by moderators Drs. Maxime Montembeault and Elise Marsan
– SORT-IN-2: Phase 1b/2a Results of a Novel Sortilin Inhibitor in GRN-FTD – Dr. Nina Schultz
– Alternative Treatments for PPA: Neurostimulation Across Languages – Dr. Kyriaki Neophytou
– Overview of The Veri-T Trial – Promoting Therapeutic Development for svPPA & Sporadic FTLD-TDP – Dr. Peter Ljubenkov
– Q&A led by moderators
Peter Ljubenkov, USA
Kyriaki Neophytou, Greece
Nina Schultz, Denmark
Peter Ljubenkov
Associate Professor of Neurology, Edward and Pearl Fein Memory and Aging Center
Director, UCSF Alzheimer’s Infusion Core (AIC), Edward and Pearl Fein Memory and Aging Center
Associate Director, Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program
University of California, San Francisco
Weill Institute for Neurosciences
Kyriaki Neophytou
Dr. Kyriaki Neophytou is an Assistant Professor of Cognitive Neuroscience and Neuropsychology at the University of Nicosia in Athens (UNIC Athens), Greece. Her research focuses on the language abilities of individuals with post-stroke and primary progressive aphasia, and related disorders such as behavioral variant frontotemporal dementia (bvFTD) and Mild Cognitive Impairment (MCI). Specifically, she studies the role of the two hemispheres in language processing and how this knowledge can inform targeted neuromodulation interventions.
Nina Schultz
Dr. Nina Schultz is Principal Research Scientist and Head of Biomarkers at Vesper Bio. She received her PhD in Neurobiology from Lund University and completed postdoctoral training in lysosomal biology at the University of California, San Francisco, followed by a second postdoctoral fellowship focused on biomarkers in neurodegeneration at Lund University. With 13 years of experience in neuroscience and biomarker research, her work centers on identifying and developing clinically meaningful biomarkers for neurodegenerative disease. At Vesper Bio, she leads the biomarker strategy underpinning the company’s clinical programs.